Amgen and AstraZeneca Report P-III (DeLLphi-305) Trial Data of Imdelltra (Tarlatamab) + Imfinzi as 1L Maintenance Treatment for ES-SCLC at ESMO 2026

Shots: Amgen & AstraZeneca reported interim P-III (DeLLphi-305) data of Imdelltra (tarlatamab) + Imfinzi (durvalumab) vs Imfinzi alone as 1L maintenance in pts (n=563) with ES-SCLC who had not progressed after Imfinzi + Pt-based CT & etoposide; presented at ESMO 2026 Presidential Symposium & published in NEJM Combination reduced risk of death by 58% (HR=0.42) with mOS of 21.1 vs 12.7mos & 1-yr OS of ~79% vs 53%; mPFS was 7.4 vs 1.9mos (HR=0.34) & ORR 26.4% vs 4.1%, with benefit across subgroups incl. brain or liver metastases Grade ≥3 TRAEs occurred in 20.9% vs 10.8% of pts; CRS was mostly Grade 1/2 (49.6%) & ICANS occurred in 1.1% Ref: Amgen  |   Image: Amgen  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Amgen and AstraZeneca Report P-III (DeLLphi-305) Trial Data of Imdelltra (Tarlatamab) + Imfinzi as 1L Maintenance Treatment for ES-SCLC at ESMO 2026 appeared first on PharmaShots.